Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

European regulators are to review Sandoz's biosimilars of the inflammatory diseases medicines, Humira and Remicade, as competition intensifies to take market share from big-selling monoclonal anti ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...